Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

被引:19
作者
Russell, Nigel H. [1 ]
Hills, Robert K. [2 ]
Thomas, Abin [3 ]
Thomas, Ian [3 ]
Kjeldsen, Lars [4 ]
Dennis, Mike [5 ]
Craddock, Charles [6 ]
Freeman, Sylvie [7 ]
Clark, Richard E. [8 ]
Burnett, Alan K. [9 ]
机构
[1] Nottingham Univ Hosp, Dept Haematol, Nottingham, England
[2] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England
[3] Cardiff Univ, Coll Biomed & Life Sci, Ctr Trials Res, Cardiff, Wales
[4] Rigshosp, Dept Haematol, Copenhagen, Denmark
[5] Christie Hosp, Dept Haematol, Manchester, Lancs, England
[6] Queen Elizabeth Hosp, Dept Haematol, Birmingham, W Midlands, England
[7] Univ Birmingham, Dept Immunol & Immunotherapy, Birmingham, W Midlands, England
[8] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[9] Btackwaterfoot, Isle Of Arran, Scotland
关键词
HEMATOPOIETIC-CELL TRANSPLANTATION; 1ST COMPLETE REMISSION; SURVIVAL; COMORBIDITY; RESPONSES; CANCER;
D O I
10.3324/haematol.2021.279010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking favorable-risk cytogenetics. Nine hundred thirty-two patients were studied, with RIC transplant in first remission given to 144 (sibling n=52, matched unrelated donor n=92) with a median follow-up for survival from complete remission of 60 months. Comparisons of outcomes of patients transplanted versus those not were carried out using Mantel-Byar analysis. Among the 144 allografted patients, 93 had intermediate-risk cytogenetics, 18 had adverse risk and cytogenetic risk group was unknown for 33. In transplanted patients survival was 37% at 5 years, and while the survival for recipients of grafts from siblings (44%) was better than that for recipients of grafts from matched unrelated donors (34%), this difference was not statistically significant (P=0.2). When comparing RIC versus chemotherapy, survival of patients treated with the former was significantly improved (37% versus 20%, hazard ratio = 0.67 [0.53-0.84]; P<0.001). When stratified by Wheatley risk group into good, standard and poor risk there was consistent benefit for RIC across risk groups. When stratified by minimal residual disease status after course 1, there was consistent benefit for allografting. The benefit for RIC was seen in patients with a FLT3 ITD or NPM1 mutation with no evidence of a differential effect by genotype. We conclude that RIC transplantation is an attractive option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics and, in this study, we could not find a group that did not benefit.
引用
收藏
页码:1518 / 1527
页数:10
相关论文
共 19 条
[1]   Age and acute myeloid leukemia [J].
Appelbaum, FR ;
Gundacker, H ;
Head, DR ;
Slovak, ML ;
Willman, CL ;
Godwin, JE ;
Anderson, JE ;
Petersdorf, SH .
BLOOD, 2006, 107 (09) :3481-3485
[2]   Therapeutic Advances in Acute Myeloid Leukemia [J].
Burnett, Alan ;
Wetzler, Meir ;
Loewenberg, Bob .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :487-494
[3]   Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia [J].
Burnett, Alan K. ;
Russell, Nigel H. ;
Hills, Robert K. ;
Kell, Jonathan ;
Freeman, Sylvie ;
Kjeldsen, Lars ;
Hunter, Ann E. ;
Yin, John ;
Craddock, Charles F. ;
Dufva, Inge Hoegh ;
Wheatley, Keith ;
Milligan, Donald .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :3924-3931
[4]   Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[5]   Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years [J].
Cornelissen, J. J. ;
Versluis, J. ;
Passweg, J. R. ;
van Putten, W. L. J. ;
Manz, M. G. ;
Maertens, J. ;
Bverloo, H. B. ;
Valk, P. J. M. ;
Kooy, M. van Marwijk ;
Wijermans, P. W. ;
Schaafsma, M. R. ;
Biemond, B. J. ;
Vekemans, M-C ;
Breems, D. A. ;
Verdonck, L. F. ;
Fey, M. F. ;
Jongen-Lavrencic, M. ;
Janssen, J. J. W. M. ;
Huls, G. ;
Kuball, J. ;
Pabst, T. ;
Graux, C. ;
Schouten, H. C. ;
Gratwohl, A. ;
Vellenga, E. ;
Ossenkoppele, G. ;
Loewenberg, B. .
LEUKEMIA, 2015, 29 (05) :1041-1050
[6]   Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 [J].
Devine, Steven M. ;
Owzar, Kouros ;
Blum, William ;
Mulkey, Flora ;
Stone, Richard M. ;
Hsu, Jack W. ;
Champlin, Richard E. ;
Chen, Yi-Bin ;
Vij, Ravi ;
Slack, James ;
Soiffer, Robert J. ;
Larson, Richard A. ;
Shea, Thomas C. ;
Hars, Vera ;
Sibley, Alexander B. ;
Giralt, Sergio ;
Carter, Shelly ;
Horowitz, Mary M. ;
Linker, Charles ;
Alyea, Edwin P. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) :4167-+
[7]   Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia [J].
Freeman, Sylvie D. ;
Virgo, Paul ;
Couzens, Steve ;
Grimwade, David ;
Russell, Nigel ;
Hills, Robert K. ;
Burnett, Alan K. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4123-+
[8]   Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results [J].
Gardin, Claude ;
Pautas, Cecile ;
Fournier, Elise ;
Itzykson, Raphael ;
Lemasle, Emilie ;
Bourhis, Jean-Henri ;
Ades, Lionel ;
Marolleau, Jean-Pierre ;
Malfuson, Jean-Valere ;
Gastaud, Lauris ;
Raffoux, Emmanuel ;
Lambert, Juliette ;
Braun, Thorsten ;
Thomas, Xavier ;
Chantepie, Sylvain ;
Cluzeau, Thomas ;
de Botton, Stephane ;
Berthon, Celine ;
Boissel, Nicolas ;
Duployez, Nicolas ;
Terre, Christine ;
de Latour, Regis Peffault ;
Michallet, Mauricette ;
Celli-Lebras, Karine ;
Preudhomme, Claude ;
Dombret, Herve .
BLOOD ADVANCES, 2020, 4 (09) :1942-1949
[9]  
Leith CP, 1997, BLOOD, V89, P3323
[10]   Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia [J].
Lim, ZiYi ;
Brand, Ronald ;
Martino, Rodrigo ;
van Biezen, Anja ;
Finke, Juergen ;
Bacigalupo, Andrea ;
Beelen, Dietrich ;
Devergie, Agnes ;
Alessandrino, Emilio ;
Willemze, Roel ;
Ruutu, Tapani ;
Boogaerts, Marc ;
Falda, Michele ;
Jouet, Jean-Pierre ;
Niederwieser, Dietger ;
Kroger, Nicolaus ;
Mufti, Ghulam J. ;
De Witte, Theo M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :405-411